XH S003
Alternative Names: XH-S003Latest Information Update: 26 Feb 2024
At a glance
- Originator S-Infinity Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I IgA nephropathy
Most Recent Events
- 22 Feb 2024 S-Infinity Pharmaceuticals plans a phase I pharmacokinetics trial (In volunteers, In adults) in China (PO, Capsule) (NCT06272747)
- 19 Jul 2023 Preclinical trials in Unspecified in China (unspecified route), prior to July 2023 prior to July 2023 (S-Infinity Pharmaceuticals pipeline, July 2023)
- 14 Jul 2023 S-Infinity pharmaceuticals plans a phase I trial in Healthy volunteers in Australia (PO)